Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
147.07B
Market cap147.07B
Price-Earnings ratio
19.86
Price-Earnings ratio19.86
Dividend yield
6.64%
Dividend yield6.64%
Average volume
32.42M
Average volume32.42M
High today
$25.94
High today$25.94
Low today
$25.66
Low today$25.66
Open price
$25.87
Open price$25.87
Volume
5.26M
Volume5.26M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$22.88
52 Week low$22.88

Stock Snapshot

The current Pfizer(PFE) stock price is $25.81, with a market capitalization of 147.07B. The stock trades at a price-to-earnings (P/E) ratio of 19.86 and offers a dividend yield of 6.6%.

On 2026-05-26, Pfizer(PFE) stock traded between a low of $25.66 and a high of $25.94. Shares are currently priced at $25.81, which is +0.6% above the low and -0.5% below the high.

The Pfizer(PFE)'s current trading volume is 5.26M, compared to an average daily volume of 32.42M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.88.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $22.88.

PFE News

Simply Wall St 10h
Pfizer Valuation Check After New HYMPAVZI Approval Vaccine Data And Oncology Collaboration

Pfizer (PFE) has put fresh clinical and regulatory news in focus, including new European approval for hemophilia treatment HYMPAVZI, promising pneumococcal vacc...

Pfizer Valuation Check After New HYMPAVZI Approval Vaccine Data And Oncology Collaboration
Nasdaq 17h
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?

Key Points Pfizer is offering investors a huge 6.6% dividend yield. The pharmaceutical giant isn't hitting on all cylinders, but dividend investors shouldn't...

This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
Nasdaq 2d
What's the Better Dividend Stock Today: AbbVie or Pfizer?

Key Points Pfizer's dividend yield is far higher than AbbVie's, but the key issue is whether the payout is safe. AbbVie has been a dividend growth beast for s...

What's the Better Dividend Stock Today: AbbVie or Pfizer?

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

Simply Wall St 3d
Pfizer Collaboration Targets Faster Cancer Trials While Shares Trade Below Value

Pfizer (NYSE:PFE) and Sarah Cannon Research Institute have agreed to work together using SCRI’s Accelero platform to speed up oncology clinical trials. The col...

Pfizer Collaboration Targets Faster Cancer Trials While Shares Trade Below Value
TipRanks 3d
Pfizer Juggles Trial Win, Setback and New Vaccine Bet

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Meet Samuel – Your Personal Investing Prophet Start...

TipRanks 4d
Pfizer’s Bevacizumab Biosimilar Study in Japan: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Sam...

TipRanks 4d
Pfizer Advances New Migraine Tablet Formulation With Phase 1 Bioequivalence Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Sam...

TipRanks 4d
Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Sam...

TipRanks 4d
Pfizer’s Phase 3 Lyme Vaccine Trial Nears the Finish Line: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Sam...

TipRanks 4d
Pfizer Terminates Early KRAS Cancer Trial: What It Means for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Sam...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.